Axogen Inc Dossier - Source-backed chat

Axogen Inc

AXGNNASDAQ

SectorHealth Care

IndustryMedical Devices

Beta (adjusted)1.10

Intrinsic Value $21.47median of 3 methodsbased on filings through 30 Jun 2026

Market Price $41.92Price as of 30 Sep 2026

OvervaluedIntrinsic value is 49% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $2.5B

Enterprise Value $2.4B

Shares Outstanding 53M diluted

Moat Rating None

Next Earnings Date28 Oct 2026

Last ex-dividend27 Jan 2010

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Axogen is a global leader in peripheral nerve repair, transitioning its flagship Avance Nerve Graft to a highly regulated, BLA-approved biologics platform. This transition, combined with a clean balance sheet following the full retirement of its Oberland debt facility in early 2026, positions the company for sustainable, high-margin growth. Strong commercial execution is evidenced by a 26.6% year-over-year revenue increase in Q1 2026, driving management to raise full-year revenue guidance to at least $270 million with positive free cash flow.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets9 analysts · as of 18 Aug 2026

Low · most bearish analyst$48.00

Mean target$53.22

High · most bullish analyst$58.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The transition to the biologics platform faces operational or supply chain bottlenecks at the Dayton/Vandalia facility, leading to inventory write-downs or gross margin compression below 72%. Slower-than-expected surgeon adoption of the BLA-regulated product or delays in commercial payer contracting limit revenue growth to the mid-teens, delaying sustained profitability.

Base CaseCentral scenario

Axogen successfully commercializes its BLA-approved Avance Nerve Graft, leveraging its 12-year exclusivity period. Reimbursement tailwinds, including higher CMS outpatient rates, drive deeper market penetration across Extremities, Oral Maxillofacial, and Breast reconstruction markets. The company achieves its raised FY 2026 revenue guidance of at least $270 million (representing over 20% growth) while maintaining gross margins within the 74% to 76% target range and generating positive free cash flow.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

BLA approval for Avance Nerve Graft establishes a highly regulated biologics platform with a potential 12-year exclusivity runway.
Elimination of debt overhang through the full repayment and termination of the $69.7 million Oberland loan facility in January 2026.
Strong liquidity position with $103.6 million in cash, restricted cash, and investments as of March 31, 2026, following an upsized public offering.
Improving reimbursement landscape with positive CMS outpatient rate adjustments and expanding commercial payer coverage.

Key Investment Risks

Concentrated product portfolio risk, with virtually all revenue derived from peripheral nerve repair products.
Near-term margin pressures from one-time regulatory costs, biologics conversion, and elevated inventory reserves.
Dependence on third-party reimbursement decisions and government regulations for healthcare procedures.
Potential dilution from stock-based compensation milestones and public equity offerings.

Thesis Invalidation Triggers

Failure to maintain gross margins above 72% due to persistent manufacturing inefficiencies or cost overruns at the Vandalia facility.
A reversal in positive reimbursement trends or negative coverage decisions by major commercial payers like Aetna.
Significant delays or negative outcomes in the FDA post-marketing requirement study comparing Avance to nerve autograft.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.